Clinical Trial

Testing Experimental Medication in Healthy Subjects

Study Description

Exploratory Evaluation of [11C]-NOP46

This is an open-label, single center design. In the first stage, five (5) healthy individuals will receive a microdose (10A?g) of [11C]-NOP46, immediately followed by whole body positron emission tomography (PET)/computed tomography (CT) to determine dosimetry and perform an initial safety evaluation of the radiotracer. If no toxicities develop, then the investigation will move to the second stage, in which thirty (30) patients with chronic pain will receive a microdose of [11C]-NOP46 followed by PET/CT of region of interests.

Location

Locations Selected Location

Methods

Pharmaceutical medication involved Pharmaceutical medication involved
Patients and healthy individuals accepted Patients and healthy individuals accepted

Drug - [11C]-NOP46

Subjects will receive a microdose (≤10 µg) of [11C]-NOP46.

Radiation - PET/CT scan

After subjects receive a microdose of [11C]-NOP46, whole body PET/CT scan(s) will be performed to determine dosimetry and perform an initial safety evaluation of the radiotracer in Stage 1 and region of interests in Stage 2.

Additional Information

Official Study Title

Exploratory Evaluation of [11C]-NOP46 Pharmacokinetics With Positron Emission Tomography (PET)

Clinical Trial ID

NCT03705819

ParticipAid ID

dR61qd